Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News 4D Molecular Therapeutics Inc FDMT

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:FDMT)

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

GlobeNewswire 3 days ago

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

GlobeNewswire 3 days ago

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

GlobeNewswire December 16, 2024

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

GlobeNewswire November 14, 2024

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire November 13, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Accesswire November 4, 2024

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire November 3, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Accesswire November 2, 2024

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire October 31, 2024

Opinion & Analysis (NDAQ:FDMT)

No current opinion is available.

Bullboard Posts (NDAQ:FDMT)

4DMT Announces Presentation at the 2024 North American Cysti

JUST IN: $FDMT 4DMT Announces Presentation at the 2024 North American Cystic Fibrosis ConferenceEMERYVILLE, Calif., Sept. 23, 2024...
whytestocks - September 23, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): A Promising B

http://beyondspx.com/2024/07/31/4d-molecular-therapeutics-inc-nasdaqfdmt-a-promising-biotech-poised-for-growth/
MikeTester - August 2, 2024

Learn to Evaluate (FDMT) using the Charts

BREAKING NEWS: $FDMT Learn to Evaluate (FDMT) using the Charts2024-07-11 10:26:00 ET Stock Traders Daily has produced this trading...
whytestocks - July 11, 2024

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 P

Just In: $FDMT 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD...
whytestocks - June 8, 2024

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Cli

News; $FDMT 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible...
whytestocks - June 6, 2024